Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 2/20 | 0.30 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29752052 | 1.00 | KEAP1 (0.31) | KEAP1NFE2L2KDM1AKDM1BMAPT | |
| SCHEMBL8114322 | 0.85 | CYP3A4 (0.37) | KEAP1NFE2L2 | |
| SCHEMBL26961128 | 0.82 | SLC9A1 (0.39) | KDM1AKDM1B | |
| SCHEMBL26961127 | 0.81 | KEAP1 (0.43) | KEAP1NFE2L2 | |
| SCHEMBL26961129 | 0.81 | KEAP1 (0.34) | KEAP1NFE2L2KDM1AKDM1B | |
| SCHEMBL7857498 | 0.79 | KHK (0.48) | KDM1AKDM1B | |
| SCHEMBL846319 | 0.78 | — | — | |
| SCHEMBL19031968 | 0.77 | — | — | |
| SCHEMBL10817777 | 0.72 | TDP1 (0.35) | KEAP1NFE2L2MAPT | |
| SCHEMBL5401553 | 0.72 | MEN1 (0.30) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4363409-B1 | METHOD FOR THE PRODUCTION OF ALKYLENE OXIDES | COVESTRO DEUTSCHLAND AG (DE) | 2025-06-11 | — | — | EP | claimed |
| CN-118479999-A | Preparation method of 3-chloro-2, 5, 6-trifluoropyridine | 帕潘纳(北京)科技有限公司 | 2024-08-13 | — | — | CN | claimed |
| US-12595255-B2 | Heteroaryl-substituted imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-12581852-B2 | Compound, luminescent material, delayed fluorescent material, and organic optical device | KYULUX, INC. (JP) | 2026-03-17 | — | — | US | disclosed |
| EP-4626860-A1 | FUSED PYRROLYL-SULFONAMIDE COMPOUNDS | ReWind Therapeutics NV (BE) | 2025-10-08 | — | — | EP | disclosed |
| US-12358875-B2 | N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as GPR17 modulators for treating CNS disorders such as multiple sclerosis | UCB PHARMA GMBH (DE) | 2025-07-15 | — | — | US | disclosed |
| US-12331027-B2 | Herbicidal pyridylethers | BASF SE | 2025-06-17 | — | — | US | disclosed |
| EP-4363409-B1 | METHOD FOR THE PRODUCTION OF ALKYLENE OXIDES | COVESTRO DEUTSCHLAND AG (DE) | 2025-06-11 | — | — | EP | disclosed |
| CN-111356684-B | Herbicidal pyridyl ethers | 巴斯夫欧洲公司 | 2025-03-28 | — | — | CN | disclosed |
| US-20240308970-A1 | METHOD FOR PRODUCING ALKYLENE OXIDES | COVESTRO DEUTSCHLAND AG (DE) | 2024-09-19 | — | — | US | disclosed |
| US-12071404-B2 | Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides | UCB PHARMA GMBH (DE) | 2024-08-27 | — | — | US | disclosed |
| US-8404856-B2 | Non-nucleoside reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-03-26 | — | — | US | disclosed |
| EP-2432555-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | Incyte Corporation (US) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010135650-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2010-11-25 | — | — | WO | disclosed |
| US-20100298334-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-20100256181-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME LLC | 2010-10-07 | — | — | US | disclosed |
| EP-2222661-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009067166-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO., INC. (US) | 2009-05-28 | — | — | WO | disclosed |
| US-7220863-B2 | Process for preparing 2-aminopyridine derivatives | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2007-05-22 | — | — | US | disclosed |
| US-20060047124-A1 | Process for preparing 2-aminopyridine derivatives | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12581852-B2 | Compound, luminescent material, delayed fluorescent material, and organic optical device | CCND2, CCND1, CCNL2 | KEAP1 742/4885NFE2L2 60/4885KDM1A 3222/4885 |
| US-20100298334-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK1, JAK3, JAK2 | KEAP1 3702/4885NFE2L2 2169/4885KDM1A 727/4885 |
| US-20060047124-A1 | Process for preparing 2-aminopyridine derivatives | KCND2, KCNJ2, KCNJ5 | KEAP1 3492/4885NFE2L2 807/4885KDM1A 1059/4885 |
| US-12358875-B2 | N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as GPR17 modulators for treating CNS disorders such as multiple sclerosis | GPR27, GPR18, GPR17 | KEAP1 2045/4885NFE2L2 1634/4885KDM1A 2157/4885 |
| US-12331027-B2 | Herbicidal pyridylethers | DDT, PLPBP, PNPO | KEAP1 314/4885NFE2L2 1828/4885KDM1A 828/4885 |
| US-12071404-B2 | Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides | GPR17, GPR18, GPR27 | KEAP1 2349/4885NFE2L2 2805/4885KDM1A 1496/4885 |
| US-20240308970-A1 | METHOD FOR PRODUCING ALKYLENE OXIDES | AOC2, SCO2, AOC3 | KEAP1 1198/4885NFE2L2 269/4885KDM1A 1835/4885 |
| US-12595255-B2 | Heteroaryl-substituted imidazole derivatives | CLIC1, CYP2B6, CYP2D6 | KEAP1 2348/4885NFE2L2 4226/4885KDM1A 1852/4885 |
| US-20100256181-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | POLB, POLR2A, RRM2B | KEAP1 4207/4885NFE2L2 3217/4885KDM1A 1012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.